Advanced search
Start date

Cannabidiol (CBD) in patients with mild to moderate symptoms of coronavirus 2019: a randomized, double-blind, placebo-controlled clinical trial


The aim of this work is to conduct a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of cannabidiol (CBD - 300 mg a day) in patients infected with SARS-CoV-2. The specific objectives are to assess whether, in patients with mild and moderate forms of SARS-CoV-2, daily use of CBD 300 mg for fourteen days is capable of: I) decrease viral load; II) modify inflammatory parameters, such as cytokines, measured from serum; II) reduceclinical and emotional symptoms through daily clinical evaluation; IV) improve the quality of life and sleep; V) reduce hospitalization and worsen the severity of the disease; v) Monitor the possible adverse effects of CBD use in these patients VI) Evaluate whether CBD 300 mg can prevent depression, burnout, PTSD and other neuropsychiatric disorders in SARS-CoV-2 patients; VII) Evaluate if CBD can prevent central structural and functional abnormalities in SARS-CoV-2 patients as assessed by DTI diffusion tensor imaging and rsfMRI - resting-state functional magnetic resonance imaging. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
CRIPPA, JOSE ALEXANDRE S.; ZUARDI, ANTONIO W.; GUIMARAES, FRANCISCO S.; CAMPOS, ALLINE CRISTINA; OSORIO, FLAVIA DE LIMA; LOUREIRO, SONIA REGINA; DOS SANTOS, RAFAEL G.; SOUZA, JOSE DIOGO S.; USHIROHIRA, JULIANA MAYUMI; PACHECO, JULIA COZAR; et al. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic A Randomized Clinical Trial. JAMA NETWORK OPEN, v. 4, n. 8, . (08/09009-2, 20/12110-9)

Please report errors in scientific publications list by writing to: